MARKET

THMO

THMO

ThermoGenesis Holdings Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.180
0.000
0.00%
After Hours: 2.160 -0.02 -0.92% 17:50 09/23 EDT
OPEN
2.190
PREV CLOSE
2.180
HIGH
2.240
LOW
2.160
VOLUME
83.27K
TURNOVER
--
52 WEEK HIGH
4.450
52 WEEK LOW
1.920
MARKET CAP
25.97M
P/E (TTM)
-1.6538
1D
5D
1M
3M
1Y
5Y
Hematopoietic Stem Cell Transplant Market Analysis By Industry Growth, Size, Share, Demand, Trends and Research Report 2029
Research Nester released a report titled "" which delivers a detailed overview of the hematopoietic stem cell transplant market in terms of market segmentation by transplant type, disease indication, application, end user, and by region.
AmericaNewsHour · 2d ago
BRIEF-ThermoGenesis Awarded NIH SBIR Phase I Grant
reuters.com · 09/14 12:39
ThermoGenesis Awarded NIH SBIR Phase I Grant to Develop Key Cell Processing Disposable for Quintessence Automated manufacturing of Gene-engineered Autologous Cell (GEAC) Therapies
ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company was awarded a $250,000 Phase I Small Business Innovation Research (SBIR) grant...
PR Newswire · 09/14 12:30
ThermoGenesis Receives $250,000 Grant to Develop Key Cell Processing Disposable for Quintessence System
MT Newswires · 09/14 11:30
Thermogenesis Holdings to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview at the H.C. Wainw...
PR Newswire · 09/07 12:30
New Strong Sell Stocks for August 31st
Zacks.com · 08/31 13:07
Recap: ThermoGenesis Holdings Q2 Earnings
Shares of ThermoGenesis Holdings (NASDAQ:THMO) decreased 2.7% after the company reported Q2 results. Quarterly Results Earnings per share rose 62.75% over the past year to ($0.38), which missed the estimate of ($0.18).
Benzinga · 08/12 21:29
ThermoGenesis Holdings Q2 EPS $(0.38) Misses $(0.18) Estimate, Sales $2.20M Beat $1.98M Estimate
ThermoGenesis Holdings (NASDAQ:THMO) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.18) by 111.11 percent. This is a 62.75 percent increase over losses of $(1.02) per
Benzinga · 08/12 20:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of THMO. Analyze the recent business situations of ThermoGenesis Holdings Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average THMO stock price target is 6.00 with a high estimate of 6.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 27
Institutional Holdings: 467.87K
% Owned: 3.93%
Shares Outstanding: 11.91M
TypeInstitutionsShares
Increased
5
212.09K
New
6
83.28K
Decreased
3
63.22K
Sold Out
4
144.43K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Office Equipment
+1.12%
Technology Equipment
+6.13%
Key Executives
Chairman/President/Chief Executive Officer/Director
Xiaochun Xu
Chief Financial Officer
Jeffery Cauble
Independent Director
Debra Donaghy
Independent Director
Russell Medford
Independent Director
Joseph Thomis
No Data
About THMO
ThermoGenesis Holdings, Inc., formerly Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It offers a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Its CAR-TXpress platform is its cellular processing platform. It offers cell manufacturing tools and services in the global cell and gene therapy market.

Webull offers kinds of Thermogenesis Holdings Inc stock information, including NASDAQ:THMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading THMO stock methods without spending real money on the virtual paper trading platform.